Summary#
Introduction 283, sponsored by Council Member Linda Lee, would amend Title 17 of the New York City Administrative Code to create a construction-site opioid antagonist program. Its stated goal is to address opioid overdoses at certain construction and demolition sites. It was referred to committee on January 29, 2026, and is not law.
- The Department of Health and Mental Hygiene (DOHMH), coordinating with the Department of Buildings, would provide five opioid-antagonist kits to a site safety professional at each qualifying site.
- A qualifying site is a project for construction or demolition of a major building where the Building Code requires a site safety professional.
- Site safety professionals must notify DOHMH when a kit is used or unusable. They may request more if fewer than five kits are kept at the site.
- DOHMH must make administration training available to all site safety professionals and to construction workers. The bill does not require workers to take the training.
- The bill sets out limited liability protections for people who administer an antagonist, and requires DOHMH to report on the program each year.
What it means for you#
- Construction sites and site safety professionals: DOHMH would provide kits without charging a fee. To request kits, a site safety professional must give DOHMH specified information, including site and worker counts. When work ends, the professional must notify DOHMH, which must coordinate collection of unused kits.
- Construction workers: Training must be available, but the bill does not require workers to attend it. A trained worker—or someone otherwise complying with applicable laws—may administer an antagonist to someone they reasonably believe is experiencing an opioid overdose.
- People who administer a kit: The bill treats its use as first aid or emergency treatment for liability purposes. A site safety professional or construction worker acting reasonably and in good faith and following the stated legal requirements would not face criminal, civil, or administrative liability solely for that action. The bill does not create a private right of action over use or failure to use a kit.
- Current rules: The supplied material does not include current law or details of existing programs, so it is not possible to verify how this would change existing city requirements or programs.
Money#
The bill requires DOHMH to provide kits and make training available, but no cost estimate is included.
- The city could have costs for kits, training, staff time, distribution, collection, and reporting; the bill gives no amounts.
- DOHMH may not charge a fee for kits provided through the program.
What is unclear#
- The bill does not say whether DOHMH must send the first five kits automatically or whether a site safety professional must request them.
- It does not set deadlines for providing or replacing kits, or explain how training will be delivered.
- It does not estimate how many sites or workers would be covered, or how much the program would cost.
- It does not specify how DOHMH will check that notices, kit counts, or training information are accurate.
Case for#
- The Council’s summary says the program is intended to address opioid overdoses at construction sites. Having kits at qualifying sites could make an antagonist available there when an overdose is suspected.
- Requiring training to be available to site safety professionals and workers could help them learn how to administer the medication.
- The bill requires annual public reporting on sites, kits, and training, which would give the public information about program activity.
Case against#
- The bill requires training to be available, but does not require site safety professionals or workers to take it.
- The bill does not set delivery timelines or explain how the initial kits will reach sites, which could affect how consistently the program operates.
- The city must provide kits and training, but the bill supplies no cost estimate or funding source.
- The required annual report counts kits and trainings, but does not require reporting on overdose reversals or other outcomes.